^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EBV-specific anti-PD1 TCR-T cells

i
Other names: EBV-specific anti-PD1 TCR-T cells, EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Associations
Company:
TCRCure
Drug class:
PD1 inhibitor
Related drugs:
Associations
2ms
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
P1/2, N=18, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
Enrollment open
|
IL2 (Interleukin 2)
|
EBV-specific anti-PD1 TCR-T cells
2ms
Enrollment open • Metastases
|
EBV-specific anti-PD1 TCR-T cells
3ms
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
P1/2, N=18, Suspended, Xinqiao Hospital of Chongqing | Trial completion date: Jan 2024 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Dec 2024
Trial completion date • Trial suspension • Trial primary completion date
|
IL2 (Interleukin 2)
|
EBV-specific anti-PD1 TCR-T cells
3ms
EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov)
P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Trial completion date: Aug 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024
Trial completion date • Trial suspension • Trial primary completion date • Metastases
|
EBV-specific anti-PD1 TCR-T cells
almost2years
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
P1/2, N=18, Recruiting, Xinqiao Hospital of Chongqing | Trial completion date: Feb 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2024
Trial completion date • Trial primary completion date
|
IL2 (Interleukin 2)
|
EBV-specific anti-PD1 TCR-T cells